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Background: Most women report negative experience about the symptoms of uterine leiomyoma (UL) in their
lives, such as abnormal uterine bleeding and pelvic pain. Many studies have been conducted about efficacy of UL
treatment, but little research has been performed about womens health related quality of life (HRQL).
Methods: This is a semi-structured, descriptive, observational, qualitative study that was performed during eight
months. Focus group (FG) interviews were performed with women attending at a tertiary hospital in Brazil, who
were consecutively included in the study. Seventy women with symptomatic UL were recruited to this study. FG
duration was one hour with mediators with 5-6 women at each group. Collected data from discussions was
processed according to thematic analysis and stored at a qualitative software.
Results: Women were negatively influenced by the presence of symptomatic UL. The major themes that were
noticed during analysis were: beliefs and attitudes towards UL; limitation to social and professional activities;
sensation of fear/unfairness/discouragement towards the symptoms and adverse effects during treatment with
GnRH analogs.
Conclusions: Symptomatic UL has a negative impact on womens HRQL. Health providers should consider such
impact when counseling women on their treatment options, since it may have an important influence in these
patients’ decision-making process. While current pharmacological treatments may improve disease specific
outcomes, such as bleeding intensity and tumor volume, they fail on actually improving quality of life.
Keywords: Uterine leiomyoma, Health related quality of life, Counseling, Qualitative research, Abnormal uterine
bleeding, Pelvic painBackground
Uterine leiomyoma (UL) is the most prevalent benign
gynecological tumor. From 100 women, 80 present this
tumor; however, only around 30% will report symptoms
[1]. Treatment of this condition has undergone a signifi-
cant transformation in recent years [2]. Novel and more
efficient drugs have been developed to treat symptomatic
UL; however, surgical procedures are still highly preva-
lent in some countries to treat UL. In the United States,* Correspondence: lgobrito@gmail.com
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reproduction in any medium, provided the orUL are the main reason for performing hysterectomies
[3] at an annual expense of 2 billion dollars [4].
The pharmacological approach for UL involves hormo-
nal and nonhormonal treatments. Progesterones gener-
ally reduce uterine bleeding that is caused by the tumors.
GnRH analogs are FDA-approved for UL and block the
hypothalamic-pituitary-ovarian hormonal axis, causing a
hypoestrogenic effect that leads to a reduction in uterine
fibroid volume. Nonhormonal treatments, involving anti-
fibrinolytics and nonsteroidal anti-inflammatory drugs
(NSAIDs), are also used [5].
Before considering hysterectomy, minimally invasive
procedures for the treatment of UL can be offered, such
as surgical hysteroscopy, uterine artery embolization
(UAE), uterine artery occlusion, high-intensity focusedd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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tomy [5]. However, factors limiting the use of these pro-
cedures include their high cost and the fact that not all
of them are provided by some public health systems,
such as in Brazil.
It is known that UL causes abnormal uterine bleeding
and pelvic pain as main symptoms, impairing womens’
health related quality of life (HRQL). However, this last
parameter was the object of fewer researches [6]. Until this
moment, there is only one condition-specific questionnaire
for UL, the Uterine Fibroid Symptom and Quality of Life
(UFS-QOL) [7]. Qualitative studies are important to
explore womens’ feelings about the impact of UL in their
lives, the barriers or problems related to pharmacological
treatment of UL and to understand their motivations for
requesting clinical and/or surgical treatment. Accordingly,
we aimed to perform an exploratory study with focus
groups addressing specific information about their personal
impression of UL.Methods
This study was conducted at our Department’s Urogyne-
cology and Gynecological/Pelvic Reconstructive Division
(HCFMRP-USP), which was created 20 years ago and
provides care for women with benign gynecological dis-
eases and urogenital disorders. Our tertiary center receives
patients from all countryside cities of São Paulo state. This
observation motivated us to study womens’views on UL.
The study concept and its objectives were explained to the
patients during their consultation. The patients were con-
secutively included in the study, and inclusion took place
for a period of eight months. Women who accepted to par-
ticipate in the study were assigned to a focus group (FG)
discussion session, after signing an informed consent form.
Our Institutional Review Board Comitê de Ética em
Pesquisa do HCFMRP-USP approved the study. We
excluded women that had already decided with his/her
physician which treatment she would do, or patients who
had some form of emotional/psychological instability that
prevented them from taking part in the discussions (n = 8).
The FG sessions [8] took place in a quiet space near
the outpatient clinic, where we had chairs arranged in a
circle. Two male gynecologists (L.G.O.B; P.S.M.) were
involved in the sessions: one served as mediator and the
other as an observer. The discussions were held accord-
ing to a guiding script and were divided into three parts.
Four to six women were included at each group, with 70
participating on total; we did not have any refusal from
the patients. Some patients from the group had reported
that they had already tried nonsurgical treatments. All
of them had been followed at our facility for at least six
months prior to the occurrence of FGs. This was
thought to be necessary because some patients were nottreated adequately before referral to our hospital accord-
ing to available guidelines for the treatment of UL.
We initially presented the study, the purpose of the dis-
cussion, and the contributions the group could make to-
wards the development of a better UL treatment. After the
introduction, the patients were given time to express any
uncertainties they had about the study. Then, the main is-
sues were approached through some questions, such as:
 What is your understanding of uterine leiomyoma
(uterine fibroids) disease?
 How has this condition affected your life?
 What are your treatment expectations?
We concluded with a summary of the discussion, clari-
fying some misconceptions that participants might have
had about the disease. None of the patients attended
more than one FG discussion; content analysis was per-
formed using a single time-point. Since the participants
were still being evaluated, and therefore, not all of them
had undergone clinical treatment or decided on the type
of treatment they wanted. The median duration time for
group discussions was 60 minutes, ranging from 30 to 93
minutes.
Each participant was issued an identification code. FGs
were recorded (Audacity version 1.3.12, Free Software
Foundation, United States) and then transcribed verbatim
to ensure that all ideas retained their original form. The
observer transcribed the recordings immediately after each
FG discussion to prevent loss of details. Transcribed state-
ments were analyzed and coded using an additional soft-
ware (Atlas Ti version 6.2, GmBH, Berlin, Germany).
Transcriptions were read by two persons (L.G.O.B, F.J.C.R)
and agreed on the themes identified.
We used content analysis [9], which identifies the main
themes and subthemes raised during the FG discussions
and the different opinions about them. The saturation
criterion was applied, such that data collection was ter-
minated when comments containing new content and
meaning could no longer be identified. Diverse content
categories were established within the themes prepared
by the researchers. Finally, after preparing the themes,
two researchers (M.S.P, G.D.A) reviewed them.Results
Table 1 comprised all sociodemographic data from the
studied patients’. Women discussed the impact of UL
and discussion categories were built, leading to four
recognizable major themes, which were: knowledge
(beliefs and attitudes) towards UL; fear, unfairness and
discouragement; changes in social and professional
activities due to bleeding and pelvic pain; and medica-
tions for UL.
Table 1 Baseline characteristics of participants
Groups variable N (%)
Age (median, years) 70 (31-53)
Marital status
Without partner 18 (25.7%)
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Our study showed that participants were concerned that
uterine leiomyoma could develop into cancer. Their fear
of such an outcome was a motivational factor for seek-
ing clinical and/or surgical assistance, and was obvious
from their facial expressions as they discussed the dis-
ease. The misconception of uterine leiomyoma as a pre-
neoplastic disease of uterine cancer was a justification to
undergo hysterectomy. While several participants had
relatives with gynecological malignant neoplasms, others
also reported acquiring this information from family
members, their partner, or acquaintances, rather than
directly from a woman who had experienced this type of
cancer.
Look, I do not know much about myoma, but I know
that we cannot allow much time to go by without
treating it, since it can then lead to another disease…
Cancer, isn’t it? We worry thinking about it because
my family, my mother’s family, all had cancer. My
mother had myoma; she did not seek care, and then
developed into cancer. (W18, 52 years)Another group of participants reported having little in-
formation about leiomyoma. Some of these women were
dissatisfied with their lack of knowledge about the dis-
ease and sought out information about it. Physicians and
media (internet and television) were their main sources
of information. The discussion indicated that the women
believed their physicians were responsible for providing
them with knowledge.
I don’t know much about it, only what the doctor tells
us, and then you get worried because it is just what
you heard, you know? (W15, 42 years)Fear, unfairness and discouragement
Women referred that bleeding and pelvic pain caused a
huge sensation of fear, especially because of the unpredict-
ability of these symptoms. Most patients had already tried
pharmacological treatment and experienced therapeutic
failures, which made them feel discouraged; they felt they
did not have enough strength to keep on trying clinical
treatment. Unfairness was another feeling reported by
women; they could not understand how they used medi-
cations correctly and they did not work.
“…I feel a lot of pain, a lot of pain…When it comes,
I sweat a lot [and] am cold…and it causes too much
pain. […] I spent one month and 20 days having
nonstop menses. The only medication that blocked the
bleeding was subcutaneous, but today I will take the
last dose that I can take and then, I am going to do
what? It’s going to start bleeding again? And the
cramps? It feels like I am having a baby! It causes
strong contractions for a week. So…I don’t think it is
fair… (W8, 47 years)
“…I am starting to bleed again, and I am scared!”
(W11, 36 years)
“…I sleep every night with that baby diaper on me…
I cannot go out because blood falls under my panties,
it goes out and spills a lot, you know…Because tampon
can not control it…” (W16, 39 years)Changes in social and professional activities due to
bleeding and pelvic pain
The participants reported that bleeding and pelvic
pain limited their domestic and social activities. Some
women reported going to hospitals after many episodes
of uterine bleeding and pelvic pain. Professional activity
was also impaired by symptoms. Many women used
their symptoms to justify their decision to undergo
hysterectomy.
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and blood started to come out and my pants were all
with blood, I needed three tampons to stop, I was
ashamed at the hospital”. (W20, 37 years)
“I am also feeling the same things. Bleeding is the
worst thing in the world. I have suffered a lot…I am
praying to God that I can have surgery because I
cannot stand it anymore. I have lost too much blood,
and I have spoken to a physician. I couldn’t walk
properly at home, so I went to the hospital and they
told me that I should go to a blood bank because I was
too anemic for surgery....I turned on the shower, and I
saw those large blood clots going down the drain…and
the drain got stuck. So I called my husband, and he
called an ambulance, because it seemed that I was
fainting”. (W10, 48 years)Adverse effects using GnRH analogs
Most medication-related complaints were associated
with the use of goserelin, which had a negative impact
on the patients’ lives. Such medication was easily recog-
nized by these women due to its subcutaneous route of
administration. Despite its beneficial effects on uterine
bleeding and pelvic pain, in general, most women re-
ported that their quality of life considerably worsened
after using this drug; they reported unpleasant vaso-
motor and urogenital symptoms usually associated with
hypoestrogenism. Add-back therapy was offered to these
patients; however, only few patients could actually use
the medication due to financial limitations.
The injection gave me some hot flashes, feelings of fear,
[as well as] a bad feeling… sometimes I could not
sleep. I could not work because of the unbearable heat;
then I started to pass out. This hot feeling came from
the injection because I didn’t have… When you lay
down on the bed, your body stays hot, totally covered
in sweat…on the blanket…It’s horrible—completely
absurd… (W8, 47 years, using GnRH analogs)
When this hot feeling caused by the treatment comes to
me, and I am sleeping, I have to take off the blanket…
Sometimes, I run to the backyard and take a hose bath
there, not even in the shower [because] the hose is
colder… Then, my family asks, ‘mom, what the hell is go-
ing on…?’ However, once I get wet I feel refreshed… An-
other thing that I noticed is that my vagina is very dry,
and when urine is released it touches the vagina, [and]
that hurts a lot. I did not have this… (W10, 48 years,
using GnRH analogs)Discussion
This study has found that women with uterine leiomyoma
had a negative impact in their quality of life when the
symptoms had started, and treatment failure with medica-
tions triggered diverse negative sensations and modified
coping strategies towards this disease. GnRH analogs
caused a quick recovery from UL symptoms; however, due
to menopausal symptoms, women reported that their
quality of life had worsened.
The wrongful association of uterine leiomyoma with
cancer was widely reported by patients during the inter-
views. However, we could not find any uterine leiomyoma
study discussing the effects of cancerophobia. In fact, the
risk for leiomyosarcoma is extremely low, and this tumor is
often incidentally detected in hysterectomy specimens [10].
Moreover, lack of knowledge of the actual physiopathology
of the disease may influence the treatment decision-making
process; therefore, it is worrisome that women do not have
adequate knowledge to make the right decision. A study
conducted in the United States divided 300 women who
were scheduled to undergo hysterectomy to treat UL into 2
groups: the first group received monthly leaflets, a DVD,
and a consent form about the surgery, and the second
group was given the chance to attend a consultation with
a health professional about the disease. Two months later,
a questionnaire showed that women in both groups had
more knowledge of the disease and expressed satisfaction
with their decision to undergo hysterectomy; however,
their treatment decisions and preferences remained the
same as before [11].
Uterine leiomyoma symptoms impaired significantly
womens’ lives. It was shown during interviews that uterine
bleeding lead to negative sensations, such as fear and un-
fairness.. These feelings impair the social and health world
of women who suffer with this disease. They are consider-
ably discouraged to keep on trying conservative treatment.
This is reinforced with a bridged pseudopathway of UL
toward uterine cancer as well as with the concept that
women should not worry about having a hysterectomy
after completing childbearing. However, some studies
showed that one of the main symptoms, vaginal bleeding,
might be ultimately overestimated. Nevertheless, physi-
cians do inquire about the severity of vaginal bleeding
during diagnosis.
Previous studies have demonstrated that the intensity
with which women complain about vaginal bleeding is
the same, whether or not they are aware that they have
UL [12]. An exploratory study using an Interpretative
Phenomenological Analysis (IPA) approach found that
women use multiple experiences and pieces of informa-
tion to understand their conditions, treatment options,
and future health expectations [13]. Individual differ-
ences in disease representation may correspond to dif-
ferences in womens’ relative stress levels. This indicates
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logical concerns of women diagnosed with this disease.
It is accepted that only large or pedunculated leiomyo-
mas can cause the pelvic pain symptom. However, some
women, especially those who are used to comparing the
size of a tumor to an object, complain of pelvic pain.
Therefore, health professionals who counsel patients
with uterine leiomyomata should explain that pelvic
pain is not always related to the presence of such
tumors, but may be associated to other pathologies, such
as adenomyosis.
This qualitative research has analyzed the patients’ sat-
isfaction after using GnRH analogs. Satisfaction with
these drugs was also investigated with other benign
gynecological diseases, such as endometriosis; a previous
study found that GnRH analogs did not lead to chronic
pain relief [14]. Initially, we did not include the use of
goserelin acetate in the present study design; however,
during FG discussions, we recognized the importance of
discussing about the use of goserelin because of its nega-
tive effect on womens’ HRQL. This observation should
be considered when prescribing such medications.
However, one of this study’s limitations was that we
were unable to longitudinally analyze our participants’
qualitative comments. We propose that it would be
useful for future qualitative studies to analyze the pa-
tients’ perceptions about their disease and the proposed
treatment over time. We also did not use any specific
questionnaire for fibroids since the only one available
(UFS-QOL) was not validated for Portuguese language.
We hope it contributes to the understanding of pa-
tients’ experiences with uterine leiomyoma, especially
among health professionals who treat this condition.
Health professionals need to comprehend individual
and cultural differences contributing to a woman’s un-
derstanding of her condition. Quality of information is
important to the patient and to all who surround her
[15]. Treatment of this pathology is multidisciplinary
(involving psychology, nursing, and many other fields).
The doctor-patient relationship, in addition to other
motivational factors, should be considered during the
patient’s decision-making process. Moreover, verbal and
nonverbal communications from the patients should be
considered. We noted during our study that the percep-
tion of care seemed quite different between patients and
clinicians, and both sides should better comprehend this
difference. This approach would help patients under-
stand why it can be difficult to choose a treatment, and
physicians comprehend how different influences on
individual women can delay them from reaching a final
decision on a specific treatment option.Competing interests
The authors declare that they have no competing interests.Authors’ contributions
LGOB conceived and designed the study, acquired and analyzed the data
and drafted/revised the article; FJCR conceived and designed the study,
analyzed the data and revised the article; MSP, GDA, HFB, LMOB participated
in analyzing data and revising the article; MMSF participated in revising the
article. All authors approved the final version of the article.
Acknowledgments
The authors thank the financial support from FAEPA (Fundação de Apoio ao
Ensino, Pesquisa e Assistência do Hospital das Clínicas de Ribeirão Preto) and
FAPEMA (Fundação de Amparo à Pesquisa do Estado do Maranhão). Dr.
Magnani helped the study during focus groups as an observer.
Author details
1Department of Gynecology and Obstetrics, Ribeirão Preto School of
Medicine, University of São Paulo, Avenida Bandeirantes, 3900, 8th floor,
Monte Alegre, Ribeirão Preto, SP, Brazil. 2Ribeirão Preto College of Nursing,
University of São Paulo, Ribeirão Preto, Brazil. 3Department of Pathology,
Ribeirão Preto School of Medicine, University of São Paulo, Ribeirão Preto,
Brazil. 4Federal University of Rio Grande do Norte, Natal, Brazil. 5Federal
University of Maranhão, São Luis, Brazil.
Received: 16 July 2013 Accepted: 24 January 2014
Published: 30 January 2014
References
1. Stewart E: Uterine Fibroids. The Lancet 2001, 357:293–8.
2. Munro M: Management of heavy menstrual bleeding: is hysterectomy
the radical mastectomy of gynecology? Clin Obstet & Gynecol 2007,
50:324–53.
3. Farquhar C, Naoom S, Steiner C: The impact of endometrial ablation on
hysterectomy rates in women with benign uterine conditions in the
United States. Int J Technol Assess Health Care 2002, 18:625–34.
4. Flynn M: Health care resource use for uterine fibroid tumors in the
United States. Am J Obstet Gynecol 2006, 195:955–64.
5. Parker W: Uterine myomas: management. Fertility & Sterility 2007,
88:255–71.
6. Williams V, Jones G, Muskopf J, Spalding J, DuChane J: Uterine fibroids: a
review of health-related quality of life assessment. J Womens Health 2006,
15:818–29.
7. Spies JB, Coyne K, Guaou Guaou N, Skyrnarz-Murphy K, Gonzales SM:
The UFS-QOL, a new disease-specific symptom and health-related
quality of life questionnaire for leiomyomata. Obstet Gynecol 2002,
99:290–300.
8. Kitzinger J: Qualitative research: introducing focus groups. Br Med J 1995,
311:299–302.
9. Bardin L: Content analysis, Volume 70. 1st edition. Lisbon: Edições; 1977:229.
10. Leung F, Terzibachian J, Gay C, Chung Fat B, Aouar Z, Lassabe C, Maillet R,
Riethmuller D: Hysterectomies performed for presumed leiomyomas:
should the fear of leiomyosarcoma make us apprehend no laparotomic
surgical routes? Gynécologie Obstétrique & Fertilité 2009, 37:109–14.
11. Soldberg L, Asche S, Sepucha K, Thygeson N, Madden J, Morrissey L,
Anderson L: Informed choice assistance for women making uterine
fibroid treatment decisions: a practical clinical trial. Med Decis Mak 2010,
30:444–5.
12. Wegienka G, Baird D, Hertz-Piccioto I, Harlow S, Hartmann K: Uterine
leiomyomas (fibroids): are bleeding symptoms more likely to be
reported after diagnosis? J Clin Epidemiol 2004, 57:318–20.
13. Nicholls C, Glover L, Pistrang N: The illness experiences of women with
fibroids: an exploratory qualitative study. J of Psychosom Obstet & Gynecol
2004, 25:295–304.
14. Denny E: Women’s experience of endometriosis. J Adv Nursing 2004,
41:641–8.
15. Kai J, Beavan J, Faull C: Challenges of mediated communication,
disclosure and patient autonomy in cross-cultural cancer care.
Br J Cancer 2011, 105:918–24.
doi:10.1186/1742-4755-11-10
Cite this article as: Brito et al.: Uterine leiomyoma: understanding the
impact of symptoms on womens’ lives. Reproductive Health 2014 11:10.
